• Clarithromycin as a CYP3A Inhibitor: Advanced Insights for C

  2026-05-15

  Explore how Clarithromycin, a potent CYP3A inhibitor, enables sophisticated investigation of drug-drug interactions and metabolism in cardiovascular and pharmacokinetic research. This article offers unique, evidence-based protocols and comparative analysis for advanced experimental design.

• RG108 DNA Methyltransferase Inhibitor: Applied Cancer Resear

  2026-05-15

  RG108 stands out as a non-nucleosidic DNA methyltransferase inhibitor that enables targeted epigenetic modulation without covalent enzyme trapping. This article explores optimized experimental workflows, practical troubleshooting, and the latest comparative insights, empowering cancer researchers to reactivate silenced genes with confidence.

• Prestained Protein Marker (Triple color, EDTA free, 10-250 k

  2026-05-14

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) delivers defined, visible molecular weight standards for SDS-PAGE and Western blot workflows that require straightforward protein size verification and transfer QC. It is not suitable for applications demanding native protein conditions, direct protein quantification, or when EDTA is required.

• α2-Adrenergic Modulation of Cholinergic Airway Tone in Horse

  2026-05-14

  This study elucidates how α2-adrenergic receptor stimulation, via agents like clonidine or xylazine, selectively inhibits cholinergic nerve-mediated airway contractions in equine distal bronchi. The antagonist Tolazoline reverses this effect, highlighting presynaptic modulation as a therapeutic target for airway obstruction.

• Baicalin Restores Adult Visual Cortex Plasticity in Amblyopi

  2026-05-13

  This study demonstrates that baicalin, a flavone glycoside from Scutellaria baicalensis, can reactivate ocular dominance plasticity and restore visual function in adult mice with amblyopia. The findings establish a mechanistic link between baicalin-mediated cortical disinhibition and functional recovery, with implications for developing new therapies targeting neuroplasticity in adult vision disorders.

• Lipo3K Transfection Reagent: Efficient Delivery for Challeng

  2026-05-13

  Lipo3K Transfection Reagent unlocks high-efficiency gene delivery, even in difficult-to-transfect cells, with minimal cytotoxicity and workflow simplicity. Integrated enhancements enable robust DNA, siRNA, and co-transfection—empowering advanced gene expression and RNA interference studies while streamlining post-transfection handling.

• Fluorescein Tyramide: Signal Amplification in IHC & ISH

  2026-05-12

  Fluorescein Tyramide is a high-sensitivity fluorescent labeling dye enabling robust signal amplification in immunohistochemistry and in situ hybridization. Its performance is validated in low-abundance target detection and is essential for workflows demanding enhanced fluorescent signal clarity.

• Redefining Apoptotic Pathways: TNF-alpha in Translational Re

  2026-05-12

  This thought-leadership article unpacks how recent advances in cell death signaling—particularly the discovery that RNA Pol II inhibition triggers apoptosis independent of transcriptional loss—redefine the strategic deployment of TNF-alpha recombinant murine protein in translational models. It integrates mechanistic insight, experimental guidance, and competitive context, culminating in a forward-looking vision for researchers seeking to harness apoptosis and immune modulation in disease modeling and therapeutic innovation.

• Cytarabine (AraC): Mechanistic Insights and Innovations in A

  2026-05-11

  Explore how Cytarabine (AraC) drives apoptosis and DNA damage studies at a mechanistic level. This article uniquely bridges molecular actions with new insights from viral cell death regulation, empowering advanced leukemia and cell death research.

• CUDC-907: Technical Parameters for Dual PI3K and HDAC Inhibi

  2026-05-11

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for controlled in vitro studies that require simultaneous modulation of PI3K/AKT signaling and histone deacetylase activity. It is optimized for cell-based oncology workflows but is not validated for diagnostic or therapeutic use.

• Comparative In Vitro Activity of Sisomicin and Tobramycin

  2026-05-10

  This study rigorously compared the in vitro efficacy of sisomicin, a novel aminoglycoside antibiotic, to established agents like tobramycin and gentamicin across over 560 clinical isolates. The findings clarify nuanced drug potency, resistance patterns, and experimental parameters vital for antibiotic selection and resistance research.

• EZH2 Inhibition Modulates SASP via cGAS-STING in SCLC Senesc

  2026-05-09

  This study demonstrates that inhibiting EZH2 mitigates the senescence-associated secretory phenotype (SASP) induced by the HDAC inhibitor SAHA in small cell lung cancer (SCLC) cells. The findings elucidate how nuclear pore protein Tpr and cytoplasmic chromatin fragments activate the cGAS-STING pathway, highlighting a novel axis for therapeutic intervention in SCLC.

• Quantitative In Vitro Evaluation of Drug Responses in Cancer

  2026-05-09

  Schwartz’s dissertation introduces a systematic approach to distinguish between drug-induced proliferative arrest and cell death in cancer cell lines, enhancing the precision of in vitro drug response assays. These findings have practical implications for optimizing anticancer screening workflows and understanding mechanisms of action.

• Integrated Genomics Reveal Immune Vulnerabilities in Mesothe

  2026-05-08

  This study applies integrated genomic profiling to uncover novel immune and cell cycle vulnerabilities in pleural mesothelioma, including frequent deletions in SUFU, RB1, and co-deletion of type I interferon and CDKN2A loci. These findings suggest new molecular targets for therapy and provide a refined map for future translational research in this aggressive cancer.

• Targeting AMPA/NMDA Receptors for Neuroprotection in Soman S

  2026-05-07

  The reference study demonstrates that dual glutamate receptor antagonism, specifically with IEM-1925, offers potent antiseizure, neuroprotective, and cognitive benefits in a rat model of soman-induced status epilepticus. These findings highlight a promising new strategy for managing organophosphorus nerve agent-induced neurotoxicity and suggest practical assay approaches for translational neuroprotection research.

466 records 19/32 page Previous Next First page 上5页 1617181920 下5页 Last page